AkiraBio is a clinical-stage company pioneering molecularly targeted precision Gene Programming™ that Turns ON or OFF genes at DNA level to treat diseases at their source.

Our pipeline is built on the Precision Genetic Medicine potential of our lead product candidate, AB1, a highly selective, potent small molecule, hemoglobin inducer. AB1 is an oral, potentially disease-modifying treatment for rare hemoglobinopathies.